Skip to main content
. 2020 May 15;217(7):e20200004. doi: 10.1084/jem.20200004

Figure 1.

Figure 1.

Vaccine responses are reduced in CMV+ young adults. (A) CMV IgG titers measured by ELISA in each cohort (UK, n = 16; Senegal, n = 40). Dashed line indicates seropositive threshold. (B) Time courses of Ebola-specific antibody responses after vaccination in both cohorts. Median and IQRs shown. Mann–Whitney analyses between cohorts at each time point (UK, n = 16; Senegal, n = 40). (C) Peak vaccine-specific antibody responses (3–4 wk after MVA vaccination, M+21/28). Kruskal–Wallis with Dunn’s post-test analysis across all three groups, P = 0.0034 (UK CMV−, n = 8; UK CMV+, n = 8; Senegal, n = 40). (D) Time courses of vaccine-specific antibody responses stratified by CMV serostatus (medians and IQRs; UK CMV−, n = 8; UK CMV+, n = 8; Senegal, n = 40). (E) IFN-γ ELISPOT responses at M+7. Kruskal–Wallis with Dunn’s post-test comparison across groups across all three groups, P = 0.096. CMV− (UK CMV−, n = 8; UK CMV+, n = 8; Senegal, n = 40). Medians shown for column graphs. Error bars indicate IQRs. SFC/106 PBMCs = spot-forming cells per million PBMCs. (F) Time courses of T cell responses measured by IFN-γ ELISPOT. Median and IQRs of responses against summed Ebola GP peptide pools. Only baseline (D0) and peak (D14, M+7) were measured in the Senegalese cohort. (UK CMV− n = 8, UK CMV+ n = 8, Senegal n = 40). *, P < 0.05; **, P < 0.01.